Bone regeneration mediated by BMP4-expressing muscle-derived stem cells is affected by delivery system by Huard, J et al.
SPECIAL FOCUS
Bone Regeneration Mediated by BMP4-Expressing
Muscle-Derived Stem Cells Is Affected by Delivery System
Arvydas Usas, M.D., Andrew M. Ho, Ph.D., M.D., Gregory M. Cooper, Ph.D.,
Anne Olshanski, B.Sc., Hairong Peng, Ph.D., M.D., and Johnny Huard, Ph.D.
This study investigated the delivery of bone morphogenetic protein (BMP)4-secreting muscle-derived stem cells
(MDSC-B4) capable of inducing bone formation in mice using collagen gel (CG), fibrin sealant (FS), and gelatin
sponge carriers. After implanting these various cell-loaded scaffolds intramuscularly or into critical-size skull
defects, we measured the extent of heterotopic ossification and calvarial defect healing over a 6-week period via
radiographic, radiomorphometric, histological, and micro-computed tomography analyses. As expected, in the
absence of MDSC-B4, there was no ectopic ossification and only minimal calvarial regeneration using each type
of scaffold. Although CG and gelatin sponges loaded with BMP4-secreting cells produced the most ectopic bone,
FS constructs produced bone with comparably less mineralization. In the mouse calvaria, we observed MDSC-
B4-loaded scaffolds able to promote bone defect healing to a variable degree, but there were differences between
these implants in the volume, shape, and morphology of regenerated bone. MDSC-B4 delivery in a gelatin
sponge produced hypertrophic bone, whereas delivery in a CG and FS healed the defect with bone that closely
resembled the quantity and configuration of native calvarium. In summary, hydrogels are suitable carriers for
osteocompetent MDSCs in promoting bone regeneration, especially at craniofacial injury sites.
Introduction
Supplemental bone grafting is often required to healcritical-size bone defects after skeletal injury in ortho-
pedic surgery, neurosurgery, and dentistry. Traditionally,
the most common source of harvested tissue includes bone
auto- and allograft, but these harvests are limited in supply
and fraught with donor site morbidities, and there are con-
cerns about disease transmission and immune rejection when
using allografts. Consequently, intensive efforts on devel-
oping alternative approaches include fabricating osteogenic,
osteoinductive, osteoconductive, and osteointegrative bone
graft substitutes. Current bone engineering strategies mainly
focus on transplanting cells embedded within supportive
matrices and biomolecules, effectively creating a ‘‘tissue en-
gineered construct’’ that has shown some success in repairing
and regenerating bone tissue capable of restoring path-
ologically altered structures.1,2 Some have described this
approach as consisting of an interactive triad of viable os-
teocompetent cells, soluble osteoinductive signals, and os-
teoconductive matrices or scaffolds.1,3
Skeletal muscle contains stem cells with the ability to dif-
ferentiate into osteoblasts under the influence of proper in-
ductive factors that have driven other progenitor cells toward
the osteogenic lineage. Muscle-derived stem cells (MDSCs)
stimulated or genetically engineered to express bone mor-
phogenetic protein (BMP)2 or BMP4 have been shown to
undergo osteogenic differentiation in vitro, form ectopic bone
in vivo, and heal bone defects of the skull and long bones.4–7 A
5-mm diameter defect in the adult mouse calvaria is unable to
heal spontaneously and has been recognized as a valid model
and a robust bed for tissue engineered bone–regeneration
strategies.8
With an abundance of delivery systems now made avail-
able to tissue engineers, selecting the appropriate biomaterial
for bone engineering is critical for a successful outcome.
In vivo, the ideal biomaterial must successfully deliver exog-
enously derived osteogenic factors and/or osteoprogenitor
cells into the bone defect, all while evading host rejection
before bone formation. Additionally, the biomaterial must
preserve the bioactivity of each transported signaling factor,
release inductive molecules at a pharmacologically desired
rate, and ultimately provide a microenvironment that permits
donor cell proliferation and differentiation. Part of providing
for this microenvironment includes maintaining the potential
space, rather than occupying it with biomaterial, so that native
osteogenic cells and blood vessels can colonize the defect
and proceed toward normal bone healing. Finally, the ideal
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delivery vehicle is completely biodegradable or integrates well
with the host’s bone.9–11 In addition to these in vivo criteria,
various in vitro features exist for the ideal delivery system,
including a biomaterial that can be easily loaded with osteo-
genic growth factors10 and multipotent stem cells,12,13 as well
as carry genetically modified cells.2
Presently, the most commonly used delivery vehicles are
inorganic bone graft substitutes, natural polymers, and
synthetic polymeric matrices, in an isolated fashion or as
composites of each other. A biomaterial that various inves-
tigators, including our group, have widely used to study
bone regeneration is the naturally derived polymer, porcine
skin gelatin sponge, called Gelfoam (Pharmacia & Upjohn,
Kalamazoo, MI), originally designed for hemostasis in the
field of general surgery.5,7,14–17 We have since shown that
MDSCs can be delivered in Gelfoam to induce ectopic ossi-
fication and successfully heal bony defects.4–7,14–16 Reports
on similar collagen sponges indicate that, when loaded with
recombinant human BMP2, this biomaterial enhances bone
formation18 and produces regenerated bone that is compa-
rable in size to regenerated bone obtained using autografts.19
As a result, many now considered absorbable collagen
sponges to be a criterion standard scaffold for bone engi-
neering.20 In part because of this, the utility of other scaffolds
in combination with MDSCs for inducing bone formation
and healing bone defects has not been widely investigated.
To this end, our laboratory has begun to demonstrate that
retrovirally transduced muscle-derived cells can proliferate
in collagen gels (CG) and repair articular cartilage defects,21
whereas BMP4-secreting MDSCs embedded in fibrin glue
can acquire a chondrocyte-like phenotype after implantation
into an osteochondral defect.22 These results prompted us to
investigate the utility of CG and fibrin sealant (FS) as de-
livery devices for BMP4-secreting MDSCs as a strategy for
bone engineering.
In this report, we present experiments involving MDSCs
isolated from post-natal murine skeletal muscle, which are
transduced with a retroviral vector encoding BMP4 or LacZ.
We compare the efficacy of each cell construct after delivery
into syngeneic mice through three different scaffolds, in-
cluding two types of hydrogels (bovine type I CG and FS), as
well as a solid-phase gelatin sponge, Gelfoam. We assessed
the efficacy of each cell–scaffold construct by measuring the
amount of bone formation in the mouse hindlimb or in a
critical-size parietal bone defect via radiographic, radio-
morphometric, histologic, and micro-computed tomography
examination over a 6-week period.
Materials and Methods
Cell isolation and retroviral transduction
We isolated MDSCs using a modified preplate technique,
as previously described,23 and transduced these cells with a
retroviral vector24 to express LacZ and BMP4 (MDSC-B4).
For the control we selected MDSCs transduced with a ret-
roviral vector–expressing LacZ reporter gene (MDSC-Lac)
that has been known to be incapable of inducing bone for-
mation. Using non-treated cells as the negative control
would not exclude the potential confounding effects related
to retroviral transduction. We also used a BMP4 bioassay to
quantify the secretion of functional BMP4 after cell trans-
duction.24
Scaffold preparation
Twelve hours before transplanting into the muscle pockets
of syngeneic mice, we harvested 2.5105 MDSC-B4 and
MDSC-Lac and separately loaded each into a 7-7-2-mm
squares of Gelfoam. We then incubated the Gelfoam at 378C
in proliferation medium (10% fetal bovine serum, 10% horne
serum, 1% penicillin=streptomycin, Dulbecco’s modified
Eagle medium) until just before surgical implantation. We
repeated this procedure with a CG (32.5mg=mL, NeuColl,
Inc., Campbell, CA) at a cell-to-gel ratio of 1:1, for a total
volume of 100mL at the time of transplantation, as well as
with a Tisseel FS (Baxter, Mississauga, ON) that was pre-
pared according to manufacturer’s instruction during the
surgery. Similarly, we prepared scaffolds for transplantation
into calvarial defects using 5.0105 MDSC-B4 or MDSC-Lac
and reducing the total volume of gels to 50mL.
Intramuscular transplantation
In accordance with the Animal Research and Care Com-
mittee of the Children’s Hospital of Pittsburgh (protocol #28-
04), each surgical procedure was performed in a sterile fashion
under general inhalation anesthesia. We divided 30 normal
(C57BL=6J) mice into three groups according to the type of
scaffold assigned to each group. Following bilateral poster-
iomedial skin incisions along the thighs, we created muscle
pockets in each hind limb. We inserted scaffolds containing
MDSC-B4 into the right limbs and control constructs consisting
of MDSC-Lac into the left limbs. After surgery, animals were
permitted unrestricted movement within their cages.
Transplantation into calvarial defect
We divided 64 normal (C57BL=6J) 12-week-old male mice
into four groups. A control group consisted of untreated mice
with a calvarial defect void of any cells or scaffolds. The other
three groups consisted of mice receiving MDSC-B4 or MDSC-
Lac loaded on Gelfoam, mixed with a CG, or mixed with a FS,
as previously described. We created critical-size parietal bone
defects using a 5-mm-diameter trephine burr (Fine Science
Tools, Inc., Foster City, CA). After recovery from anesthesia,
animals were permitted unrestricted movement within the
cage. All mice were euthanized 6 weeks post-operatively.
Radiographic evaluation
Using a Faxitron specimen radiography system (MX-20,
Faxitron X-ray Co, Wheeling, IL), we monitored for the
presence of ectopic bone at 3 and 6 weeks post-intramuscular
implantation and calvarial defect healing at 6 weeks post-
operatively. Each skull specimen was harvested and fixed in
10% neutral buffered formalin for 24h and subsequently
transferred into 70% ethyl alcohol. After removing soft tissues,
including brain substance, from each skull, we radiographed
each specimen using diagnostic x-ray film (X-OMAT V,
Kodak, Rochester, NY). Radiographs were scanned at 1200
dpi using the Microtek ScanMaker 9800XL (Microtek, Carson,
CA). Additionally, we measured ectopic bone area and den-
sity along each hind limb, as depicted radiographically, using
Northern Eclipse software, version 6.0 (Empix Imaging,
Cheektowaga, NY). We then calculated the area of re-
generated calvarial bone by subtracting the area of each skull
defect remaining at 6 weeks from the original defect area
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measured at the time of surgery. We then compared mean
bone regeneration area of the various treatment groups.
Histological evaluation and detecting
ectopic bone mass
We harvested thigh muscles containing ectopic bone at 3
and 6 weeks after intramuscular implantation to evaluate
the histology of these tissues. We froze each harvest in 2-
methylbutane pre-cooled in liquid nitrogen in preparation for
cryostat- sectioning of each tissue; each section was performed
at a thickness of 7mm. We then prepared each slide with von
Kossa stain to reveal mineralized matrix and quantified the
ectopic bone mass according to dry weight for the remaining
specimens harvested after 6 weeks. From these latter tissues,
we carefully detached the muscles and soft tissues affixed to
each bone nodule, air-dried each nodule for 1 h at room
temperature, and weighed each nodule using an analytical
balance (AG 204, Mettler-Toledo, Inc., Columbus, OH).
Micro-computed tomography analysis
We assessed calvarial bone healing at 6 weeks after scaffold
implantation using micro-computed tomography (mCT 40,
Scanco Medical, Switzerland). We scanned at least three sam-
ples from each scaffold and MDSC-B4 treatment group that
exhibited substantial healing on X-rays. Each skull was scanned
in its entirety at an isotropic resolution of 30mmover an average
scan time of 70min per sample. From these scans, we generated
three-dimensional renderings by thresholding to segment each
16-bit gray-scale image.Wealso calculated the regeneratedbone
volume (mm3) and regenerated bone mineral density (mg hy-
droxyapatite (HA)=cm3) within the original defect for each
treatment group using Scanco evaluation software, Scanco
Medical, Switzerland. We also determined the density of the
normal calvarial bone outside the zone of the initial defect to
compare the bone mineral densities of the regenerated and na-
tivebone for eachgroupofmice that receiveddifferent scaffolds.
Statistical evaluation
We performed statistical analyses using a one-way anal-
ysis of variance multiple comparison and Student t test.
Means and standard deviations for bone volume and bone
density measurements were compared using the Kruskal-
Wallis and Mann-Whitney U test. For all statistical tests,
p< 0.05 was considered to be statistically significant.
Results
Ectopic ossification in muscle
Within 3 weeks of the intramuscular implantation of
MDSC-B4, there was radiographic evidence of heterotopic
ossification along the experimental hind limbs, whereas this
was not the case for control limbs implanted with any type
of scaffold containing MDSC-Lac (data not presented). We
confirmed the deposition of mineralized extracellular ma-
trix using histology from tissue harvested along the sites
of MDSC-B4 implantation. Based on results from radio-
morphometry, there was a larger area of bone in the Gelfoam
and CG implant groups than in the FS implant group. Al-
though this difference in the area of ectopic bone was not
statistically significant when comparing the Gelfoam and CG
groups, the FS group had a significantly smaller area than
the CG group (data not presented).
By the end of the sixth week after the hind limb implan-
tation of MDSC-B4-seeded scaffolds, the radiographic evi-
dence of heterotopic ossification was even more pronounced
(Fig. 1A–C). Whereas Gelfoam and CG implants demon-
strated robust bone formation according to von Kossa stain-
ing, the FS implants displayed signs of impeded matrix
mineralization (Fig. 1D–F). Based on our radiomorphometry
analysis, we were able to detect a difference between the
Gelfoam and CG implants, the former of which had a sig-
nificantly larger area of ectopic bone. As expected from our
histological analyses, the ossification area in the FS implant
group was significantly smaller than in the other two groups
(Fig. 2A). Although there was no statistical difference between
the Gelfoam and CG implant groups in radiographic bone
density, mice from each of these groups developed bone that
was significantly denser than in the FS group (Fig. 2B).
Neither radiographic nor histological examination at this
time showed formation of heterotopic bone in the left hind
limbs implanted with MDSC-Lac-seeded scaffolds.
According to quantitative analysis of ectopic bone based
on dry weight, the Gelfoam and CG implants significantly
outperformed the FS implants in terms of ectopic bone pro-
duction after the delivery of MDSC-B4, with mean nodule
weights of 0.19 0.07 g, 0.2 0.01 g, and 0.06 0.02 g, re-
spectively (Fig. 2C).
Calvarial defect healing
Depending on the type of cells and scaffold transplanted,
there were variable degrees of healing along the parietal bone
defect detected using radiographic and radiomorphometric
evaluation during the sixth post-operative week. Overall,
the untreated mice had only a small area of regenerated
bone (2.35 1.78mm2, n¼ 10). By contrast, mice treated with
MDSC-Lac healed slightly better, with almost identical re-
generated bone surface area in the Gelfoam (5.72 1.74mm2,
n¼ 10), CG (5.7 1.69mm2, n¼ 10), and FS ((5.31 0.91mm2,
n¼ 8) groups (Fig. 3A, C, E, G). Mice treated with MDSC-
B4-seeded scaffolds exhibited greater calvarial ossification
than those treated with MDSC-Lac constructs. Regarding re-
generated bone, the Gelfoam and FS scaffolds displayed sig-
nificant gains, with full defect closure and the largest mean
area of regenerated bone (19.58 0.11mm2, n¼ 7) occurring
in the Gelfoam group (Fig. 3B, G). In comparison, eight of the
10 animals treated with MDSC-B4-seeded FS implants
showed complete or nearly complete defect healing, whereas
the other two had patent defects with only trace evidence of
ossification (mean regenerated bone area 16.03 4.03mm2,
n¼ 10) (Fig. 3F, G). In the eight mice treated with MDSC-B4-
seeded CG implants, healing was complete in four, and there
was only minimal osteogenesis in the other four (mean re-
generated bone area 11.7 7.04mm2, n¼ 8) (Fig. 3D, G). Al-
though the area of regenerated bone with MDSC-B4 was
significantly larger in the Gelfoam implant group than in mice
receiving CG and FS scaffolds, the difference between these
two latter groups was insignificant.
m-CT analysis of regenerated bone
From the mice with radiographic evidence of complete
healing after treatment with MDSC-B4, we selected at least
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FIG. 1. Ectopic bone formation at 6 weeks after intramuscular transplantation. (A–C) Radiographic examination revealed
the presence of ectopic bone at implantation sites of bone morphogenetic protein 4–secreting muscle-derived stem cells
(MDSC-B4) but not at implantation sites of MDSCs transduced with a retroviral vector–expressing LacZ reporter gene
(MDSC-Lac) in each scaffold group. (D–F) Deposition of mineralized matrix within the thigh muscles receiving MDSC-B4
implants detected using von Kossa histological staining. Original magnification: 40. Color images available online at
www.liebertonline.com=ten.
FIG. 2. Radiomorphometric and bone mass analysis of
heterotopic bone at 6 weeks. (A) Bone area, (B) bone density,
(C) bone weight. Data represent means standard devia-
tions; n¼ 3; *p< 0.05.
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three animals from each scaffold group to perform mCT
analysis of the regenerated bone (n¼ 3 in CG, n¼ 4 in Gel-
foam, and n¼ 5 in FS) This analysis consisted of two- and
three-dimensional reconstruction imaging of the repaired
defects, which revealed substantial differences in the volume
and morphology of regenerated bone with each type of
scaffold (Fig. 4A, B). There was extensive, protuberant, and
apparently hypertrophic regenerated bone in the Gelfoam
implant group, whereas defects treated with CG or FS im-
plants were filled with allometric amounts of regenerated
bone, each with a normal shape and compact structure. The
differences in regenerated bone volume between the differ-
ent delivery device groups were considerable, with close to
10 times more bone along the heavily ossified Gelfoam
(102.85 51.4mm3) than on CG (11.57 0.6mm3) or FS
(12.02 6.2mm3) implantation sites (Fig. 5A). In spite of this,
the differences in bone mineral density between these three
groups were not statistically significant (618.19 5.6mg
HA=cm3 in Gelfoam, 643.52 1.4mg HA=cm3 in CG, and
637.9 26.6mg HA=cm3 in FS). When comparing these
densities with those of the adjacent native tissue, those of
regenerated bone were significantly lower than normal bone
(754.02 79.8mg HA=cm3) (Fig. 5B).
Discussion
Ex vivo gene-based therapies involve the addition of ge-
netic material to cells in vitro and the subsequent transplan-
tation of the genetically altered cells. The use of ex vivo gene
therapy necessitates the selection of the optimal transgene,
the choice of an appropriate cell population, and the selec-
tion of an appropriate scaffold to deliver cells to the site
of desired activity. The delivery of growth factors of the
BMP family has often been employed in similar studies,
because these factors can alter the differentiation pathways
of progenitor cells toward the osteogenic pathways.25–27
Investigators have used many different cell populations
in ex vivo gene-based therapies designed to promote bone
healing, including bone marrow stromal cells,28 adipose
tissue–derived cells,29 fibrous tissue–derived cells,30 and
skeletal muscle–derived cells.4–7
Biomaterials developed from natural polymers have
captured the interest of tissue engineers because of their
biocompatibility, ease of remodeling, and superior cell ad-
hesiveness, all of which are important for regenerating bone
successfully.11 A variety of naturally derived polymeric
materials, including collagen, fibrin, gelatin, agarose, hya-
luronate, and alginate, have been recently investigated in
combination with various growth factors and cell lines to
enhance osteogenesis.31–33 The relatively novel approach has
garnered particular interest in biomaterials that transform
from liquid to more-solid phases after implantation. This
morphological property provides delivery devices with the
advantage of being able to carry osteoinductive molecules or
cells while being administered through less-invasive means
such as local injection or arthroscopy, each of which elimi-
nates larger surgical exposure for implantation. Although the
mechanical strength of hydrogel-based biomaterials has
come into question when considering their application for
skeletal regeneration, these delivery devices nonetheless
provide a matrix for accelerated tissue formation that in turn
will provide desirable mechanical integrity.34
FIG. 3. Calvarial defect healing 6 weeks post-implantation.
(A–F) Representative radiographs of bone healing in differ-
ent treatment groups. (G) Radiomorphometric evaluation of
the regenerated bone area in the various treatment groups.
Data represent means standard deviations; *p< 0.05;
#p< 0.05 vs muscle-derived stem cells transduced with a
retroviral vector–expressing LacZ reporter gene treatment
groups. GF, Gelfoam; CG, collagen gel; FS, fibrin sealant.
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Of all the biomaterials derived from naturally occurring
polymers for tissue engineering, collagen-based delivery
devices are the most popular because of their ubiquitous
presence in tissues, low immunogenicity, and complete re-
sorption. In vitro and in vivo studies have shown that these
types of vehicles can deliver bioactive agents with controlled
and sustained release.10 In our study, we used a highly pu-
rified bovine type I CG that is currently in clinical use and
has a greater density than other conventional hydrogels.35
This gel is particularly appealing because it can be easily
manipulated at room temperature, at which it is in its semi-
viscous phase, whereas upon exposure to a temperature of
FIG. 5. Micro-computed tomography analysis of the regenerated calvaria. (A) Bone volume, (B) bone mineral density. Data
represent means standard deviations; n¼ 5 in fibrin sealant, n¼ 3 in collagen gel; n¼ 4 in Gelfoam; *p< 0.05 for bone
volume and p< 0.001 for bone density.
FIG. 4. Reconstruction of
mice calvaria using micro-
computed tomography. (A)
Two- dimensional reconstruc-
tion of three MDSC-B4-treated
samples in each scaffold
group, (B) three-dimensional
reconstruction of representa-
tive sample in each scaffold
group. (GF, Gelfoam; FS,
fibrin sealant; CG, collagen
gel).
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378C, the phase becomes solid. Although most CG have re-
portedly been able to enhance osteogenesis,36–38 it is impor-
tant to note that this particular gel exhibited an inherent
inhibitory effect on cell proliferation, matrix production, and
bone mineralization39 and thus was proposed to prevent
bone formation along cranial suture sites.40 Contrary to these
reports, however, we observed robust mineralization with
the largest amount of ectopic bone in mice treated with these
gels after being loaded with MDSC-B4. We further observed
near-complete closure of the calvarial defects treated with
this delivery construct, albeit with a 50% incidence of ex-
tensive bone regeneration.
We believe that a delay in the collagen phase transfor-
mation from a liquid to a solid immediately after implanta-
tion can explain the variable degrees of defect closure after
the implantation of MDCS-B4-loaded CG. Such a delay
would have caused the liquid delivery device to leak out
along the defect borders. We would like to propose two
explanations for why this may have occurred. One possi-
bility is that there may have been slight but biologically
significant differences in ambient temperature that we were
unable to control for at the time of surgical implantation,
potentially resulting in a longer time lapse for phase changes
to occur in situ from a gel to a solid biomaterial. The other
possibility is that the cell-to-gel ratio of 1:1 that we used in
these experiments may not be optimal; reducing the quantity
of cells and using a more-concentrated CG may increase the
viscosity of our construct, potentially preventing material
leakage and cell dissemination. We have based the latter
explanation on our preliminary in vitro experiments, in
which we tested the effect of gel density on MDSC prolifer-
ation and revealed that ratios of 1:2 and 1:3 resulted in larger
cell counts within the gels incubated in proliferation medium
for 8 days (unpublished data).
Fibrin, another frequently used delivery vehicle, is a nat-
ural scaffold that forms during wound healing and is im-
portant for hemostasis. Fibrin has been widely used in tissue
engineering over the past 3 decades to deliver cells and
bioactive substances. Regarding bone engineering, a re-
ported advantage that fibrin has over several other bioma-
terials is that it is a physiologic delivery system for bone
morphogenetic protein,41 beta fibroblastic growth factor, and
vascular endothelial growth factor,42 as well as platelets
containing angiogenic, mitogenic, and osteogenic growth
factors,43 because fibrin is normally packaged with these
substances. Additionally, several studies report that fibrin
glue is highly conducive to the proliferation and differenti-
ation of osteogenic cells33,44–46 and may thereby provide a
highly suitable vehicle for the clinical application of bone
regeneration. In spite of these favorable reports supporting
the use of fibrin-based delivery devices, some investigators
have also reported difficulty with bone formation after the
subcutaneous implantation of fibrin gel mixed with bone
marrow stromal cells32 and have subsequently proposed that
fibrin may physically impair osteogenesis.43 This is consis-
tent with our experimental results, in which there was de-
layed ossification and a reduction in ectopic bone formation
after the implantation of MDSC-B4-loaded fibrin gels into the
hind limbs of our experimental mice. This indicates that the
aforementioned construct is less conducive than CG and
Gelfoam to extra-skeletal ossification. In regards to healing
calvarial defects, however, this cell-fibrin gel composite was
successful, with 80% of the MDSC-B4-treated mice exhibiting
near-complete defect closure within 6 weeks of transplanta-
tion. We observed a significant difference in the extent of
bone healing between MDSC-B4 and the control MDSC-Lac
in the FS and Gelfoam treatment groups that corresponded
to a 202% and 242% greater mean area of regenerated bone,
respectively. In fact, the FS group had a larger albeit statis-
tically insignificant mean area of regenerated bone in com-
parison to the mice receiving CG implants.
As proposed for collagen implants, we believe that the
concentration of the components used to fabricate FS can
affect cell behavior within the gels. The existing commercial
fibrin products consist of two human plasma–derived com-
ponents: a highly concentrated fibrinogen complex (FC)
composed primarily of fibrinogen and fibronectin along
with catalytic amounts of factor XIII and plasminogen and
a high-potency thrombin. Prior studies demonstrated that
the behavior of human dermal fibroblasts and human mes-
enchymal stem cells in fibrin gels in vitro depends on
the FC:thrombin concentration ratio. Specifically, fibroblast
proliferation and migration are optimal in formulations
containing a fibrinogen concentration ranging between 17
and 25mg=mL, as well as a thrombin concentration of 167 to
250U=mL.47 Formulations containing a low FC concentra-
tion supported the growth of human mesenchymal stem
cells, whereas high FC concentrations offered a potential for
their osteogenic differentiation.33 The Tisseel FS that we used
in our experiments contained 75 to 115mg=mL of fibrinogen
and 400 to 600U=mL of thrombin. The results from this
study as well as those from our prior experience with re-
pairing osteochondral defects22 strongly indicate that this FS
formulation is conducive to MDSC proliferation. From this
data, we believe that it is important to further examine other
formulations of FS to determine which concentrations of in-
gredients would be optimal for MDSC proliferation and
differentiation, as well as for the secretion of growth factors.
Among the major challenges in bone tissue engineering,
regulating the amount and form of regenerated tissue is of
paramount importance. We noticed a formidable difference
in the shape and morphology of the regenerated bone within
calvarial defects when comparing the results from each un-
ique scaffold. In particular, we identified hypertrophic bone
in the Gelfoam–MDSC-B4 group, with a predominance of
outward bony protrusion and only a slight amount of bony
intracranial intrusion. By contrast, in the CG and FS groups
receiving the same type of cells, the regenerated bone closely
resembled native calvarium, with a normal configuration
that appeared diploic and had a relatively level surface.
Furthermore, the volume of regenerated calvarial bone was
nearly 10 times larger for the Gelfoam than for the CG and
FS, as demonstrated using mCT analysis.
In conclusion, we demonstrate that the selection of deliv-
ery vehicles can affect bone formation and healing. Although
a direct correlation between ectopic and orthotopic ossifica-
tion remains to be shown for the same cell-delivery vehicle,
our findings indicate that a more clinically relevant method
for testing cell–scaffold constructs is to implant them directly
along the site of the bone injury as opposed to studying the
outcomes of implanting these constructs subcutaneously or
intramuscularly. In our experiments, the CG and FS pro-
vided suitable scaffolds for MDSC-mediated bone engineer-
ing; this was particularly true of osteogenesis along the sites
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of bone injury. Injectable hydrogels provide an alternative
method for bone grafting that can be of great clinical import
when the supply of more-conventional bone grafts, such as
allo- or autografts, is limited. This is also an excellent bone
substitute for certain applications that require limited bone
repair of delicate anatomical structures, such as the cranium,
where mechanical stiffness is less important. Finally, the re-
sults from our study can pave the way for developing novel
tissue-engineering techniques, ultimately assisting surgeons
in the reconstruction of skeletal defects.
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